It’s not easy for stakeholders with widely varying interests to collaborate effectively in a consortium. The experience of the Biomarkers Consortium offers five lessons on how to successfully navigate the challenges that arise.
Eric Knight, Joel Cutcher-Gershenfeld, and Barbara Mittleman
Society’s biggest challenges are also its most complex. From shared economic growth to personalized medicine to global climate change, few of our most pressing problems are likely to have simple solutions. Perhaps the only way to make progress on these and other challenges is by bringing together the important stakeholders on a given issue to pursue common interests and resolve points of conflict.